In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis and to resolve steatohepatitis with no worsening of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback